BPC-157 15mg / TB-500 15mg Blend

This is the same two-peptide combination as the standard BPC-157/TB-500 Blend, formulated at a higher total peptide mass per vial (15mg of each, 30mg combined) rather than the more common lower-concentration versions. It is generally intended for longer or higher-volume research protocols, such as addressing more severe or chronic injuries, or simply reducing how frequently a new vial must be reconstituted. The underlying evidence base is the same as the standard-concentration blend, preclinical and animal data on each peptide individually, with no controlled studies of the fixed combination. A higher total vial concentration does not necessarily imply a proportionally greater effect at a given per-injection dose, and higher per-injection amounts may carry a greater likelihood of local side effects. It is not approved for human medical use. Reported benefits include supports tendon and ligament tissue repair in preclinical research, associated with reduced local inflammation, convenient for longer or higher-volume recovery protocols.

Reported ranges run 0.3-1 mg. A low protocol is 0.3 mg once daily, and a high protocol is 1 mg twice daily. This is reference information, not a dosing recommendation.

As with the standard-concentration blend: BPC-157 is reported at roughly 4 hours, while TB-500 is described as persisting for a much longer duration, on the order of days.. That is what sets the dosing frequency, and it is why the timing guidance is morning, or split am/pm.

Subcutaneous: into fat, under the skin. Injected subcutaneously the same way as the standard-concentration blend; the higher total vial content is intended to reduce how often a vial needs to be reconstituted over a longer protocol, not to change per-injection technique.

4-6 weeks on, followed by 2-4 weeks off. The larger vial size is often used to support multiple sequential cycles, or a single extended cycle, from one reconstitution rather than implying a different cycling schedule.

Reported side effects include mild nausea, head rush or lightheadedness, injection site redness or irritation, potentially more pronounced at higher per-injection volumes, lethargy (more often reported with tb-500). Evidence level for this compound is moderate evidence.